

Special Issue

Glaucoma: The Mechanisms and Novel Therapeutic Approaches

Message from the Guest Editor

Glaucoma remains a leading cause of irreversible blindness worldwide, primarily driven by elevated intraocular pressure and impaired aqueous humor outflow. This Special Issue will focus on the molecular and physiological mechanisms underlying ocular pressure regulation and their implications for glaucoma and related disorders. We invite authors to submit contributions that explore autophagy, intraocular pressure (IOP) dynamics, ocular hypertension, and aqueous humor outflow facility. **Topics of Interest**

- Gene-editing approaches for glaucoma therapy (e.g., CRISPR/Cas systems).
- Epigenetic modifications in glaucoma.
- Role of small RNAs in IOP regulation and neuroprotection.
- Novel biomarkers for glaucoma diagnosis and progression monitoring.
- Translational studies targeting outflow facility and neuroprotection.
- Therapeutic strategies integrating molecular and physiological insights

Guest Editor

Dr. Samantha Sze Wan Shan

1. School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China
2. Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China
3. Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Hong Kong, China

Deadline for manuscript submissions

30 April 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/265391

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).